Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) EBIT Margin (2023 - 2025)

Iovance Biotherapeutics has reported EBIT Margin over the past 4 years, most recently at 84.66% for Q4 2025.

  • Quarterly results put EBIT Margin at 84.66% for Q4 2025, up 3282.0% from a year ago — trailing twelve months through Dec 2025 was 153.08% (up 8785.0% YoY), and the annual figure for FY2025 was 153.08%, up 8785.0%.
  • EBIT Margin for Q4 2025 was 84.66% at Iovance Biotherapeutics, up from 140.69% in the prior quarter.
  • Over the last five years, EBIT Margin for IOVA hit a ceiling of 84.66% in Q4 2025 and a floor of 46254.62% in Q2 2023.
  • Median EBIT Margin over the past 3 years was 245.76% (2025), compared with a mean of 10397.37%.
  • Biggest five-year swings in EBIT Margin: surged 4592699bps in 2024 and later skyrocketed 1142bps in 2025.
  • Iovance Biotherapeutics' EBIT Margin stood at 25156.85% in 2023, then soared by 100bps to 117.48% in 2024, then increased by 28bps to 84.66% in 2025.
  • The last three reported values for EBIT Margin were 84.66% (Q4 2025), 140.69% (Q3 2025), and 189.78% (Q2 2025) per Business Quant data.